NasdaqGS:RXRXBiotechs
Recursion Pharmaceuticals (RXRX) Is Up 10.6% After Expanding AI Partnerships and Acquiring Exscientia
Recursion Pharmaceuticals has recently expanded its AI-powered drug discovery capabilities through high-profile collaborations and the acquisition of Exscientia, adding over 20 new programs and increasing milestone opportunities to over US$20 billion.
These alliances with major technology and pharmaceutical partners, including NVIDIA and Google Cloud, highlight an accelerating pace of innovation and operational scale in data-driven drug development.
We'll look at how Recursion's...